Head-to-head evidence
ozanimod vs Ponesimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline
ozanimod · Zeposia
Marketed by Bristol-Myers Squibb
NCT01628393 · Phase 2/3 · completed
The trial was randomized, placebo-controlled and fully blinded in 258 participants, and both ozanimod doses significantly reduced new brain lesions on MRI versus placebo. Because the primary measure was an imaging biomarker rather than a clinical outcome such as relapse rate or disability, this trial supports but does not on its own confirm a clinical benefit.
Next expected readout: August 2028 · NCT06529406 (registry estimate)
Ponesimod
Marketed by Vanda Pharmaceuticals
NCT02425644 · Phase 3 · completed
This large, randomized, double-blind trial compared ponesimod head-to-head against an approved active comparator (teriflunomide) using relapse rate, a core clinical measure of multiple sclerosis activity, and ponesimod met its primary endpoint with a statistically significant roughly 30% relative reduction in relapses.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ozanimod's landscape · Ponesimod's landscape